Comparison of the phenotype and clonogenicity of normal CD34+ cells from umbilical cord blood, granulocyte colony-stimulating factor-mobilized peripheral blood, and adult human bone marrow
Abstract
Bone marrow (BM) is most frequently used to transplant hematopoietic progenitor cells, but umbilical cord blood (UCB) and mobilized peripheral blood (PB) provide alternative sources of progenitor cells for transplantation. To study whether the clonogenicity and phenotype of progenitor cells vary between the compartments, CD34+ cells from UCB, mobilized PB, and BM were analyzed for in vitro colony formation and characterized by immunophenotyping for several lineage-associated and maturation-related cell surface molecules. We found that circulating CD34+ cells, either from PB after granulocyte colony-stimulating factor (G-CSF) mobilization or from UCB, contained a large proportion of cells (86-96%) with myeloid cell-associated molecules (CD33 and CD13) and clonogenic cells (colony-forming unit-granulocyte-macrophage and burst-forming unit-erythrocyte) in excess of BM CD34+ cells. Further, UCB and PB CD34+ cells contained > or = 3% cells with a phenotype associated with immature (HLA-DR- and CD38-) progenitor cells, which was comparable to what is found among BM CD34+ cells. The proportion of CD34+ cells in UCB expressing the B cell-associated molecules (CD10 and CD19) was comparable to that found in mobilized PB (< or = 5%) but s...Continue Reading
References
Citations
Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types.
Related Concepts
Related Feeds
Blood And Marrow Transplantation
The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.
Allogenic & Autologous Therapies
Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.